On this page
India flags Abhayrab rabies-vaccine batch as substandard, probes possible counterfeit
India’s drug regulator flagged Abhayrab batch KE25012 as substandard after a potency-test failure and is probing possible counterfeiting. Officials ordered vigilance over its distribution; the vaccine maker previously reported a separate counterfeit batch in 2025.
Reported figures
From the report. Source details below
| More than | 210 million doses supplied |
|---|
Also in the report
- 40% domestic rabies-vaccine market share
- Estimated 5,726 annual human rabies deaths
Other figures
- Batch KA24014
What to track next
- Reported adverse events, treatment failures, or hospital advisories connected to the flagged batch.